Overview

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the pathophysiology of the disease.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.